Obesity, Inflammation, and Cancer

Annual Review of Pathology: Mechanisms of Disease

Volumn 11, Issue , 2016, Pages 421-449

  Deng, Tuo ^a,b   Lyon, Christopher J ^a   Bergin, Stephen ^c,d   Caligiuri, Michael A ^d   Hsueh, Willa A ^c  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Adipokine; Adipose tissue; Body mass index; Cancer risk; Cytokine; Metabolic dysregulation; Weight loss

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHEMOKINE; CYTOKINE; ESTROGEN; HORMONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; NEU DIFFERENTIATION FACTOR; OSTEOPONTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE DERIVED STEM CELL; ADIPOSE TISSUE; ADIPOSE TISSUE CELL; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; COLORECTAL CANCER; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOCRINE GLAND; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNITY; INFLAMMATION; INSULIN RESISTANCE; LIVER CANCER; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; COMPLICATION; NEOPLASMS; PATHOLOGY;

ADIPOCYTES; ADIPOSE TISSUE; HUMANS; INFLAMMATION; NEOPLASMS; OBESITY;

EID: 84971310275     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012615-044359     Document Type: Article

References (186)

1. World Health Organ. 2015. Obesity and Overweight. Geneva: WHO Media Centre. http://who.int/mediacentre/factsheets/fs311/en/
2. Ogden CL, Carroll MD, Kit BK, Flegal KM. 2014. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311:806-14
3. Aggarwal BB, Vijayalekshmi RV, Sung B. 2009. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer. Res. 15:425-30
4. Calle EE, RodriguezC,Walker-Thurmond K,ThunMJ. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348(17):1625-38
5. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, et al. 2015. Global burden of cancer attributable to high body-mass index in 2012: A population-based study. Lancet Oncol. 16:36-46
6. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, et al. 2008. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 25:2097-116
7. Hanahan D, Coussens LM. 2012. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309-22
8. Kim S, Karin M. 2011. Role of TLR2-dependent inflammation in metastatic progression. Ann. N. Y. Acad. Sci. 1217:191-206
9. Moore LL, Chadid S, Singer MR, Kreger BE, DenisGV. 2014. Metabolic health reduces risk of obesityrelated cancer in Framingham Study adults. Cancer Epidemiol. Biomark. Prev. 23:2057-65
10. MacDougald OA, Burant CF. 2007. The rapidly expanding family of adipokines. Cell Metab. 6:159-61
11. Martinez-Santibanez G, Cho KW, Lumeng CN. 2014. Imaging white adipose tissue with confocal microscopy. Methods Enzymol. 537:17-30
12. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, et al. 2008. Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance. Cell Metab. 7:496-507
13. Ricardo-Gonzalez RR, Red Eagle A, Odegaard JI, Jouihan H, Morel CR, et al. 2010. IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. PNAS 107:22617-22
14. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, et al. 2011. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332:243-47
15. Molofsky AB, Nussbaum JC, Liang HE, Van Dyken SJ, Cheng LE, et al. 2013. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J. Exp. Med. 210:535-49
16. Zeyda M,Wernly B, Demyanets S, Kaun C, Hammerle M, et al. 2013. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int. J. Obes. (Lond.) 37:658-65
17. Hams E, Locksley RM, McKenzie AN, Fallon PG. 2013. Cutting edge: IL-25 elicits innate lymphoid type 2 and type II NKT cells that regulate obesity in mice. J. Immunol. 191:5349-53
18. Huang Q, Niu Z, Tan J, Yang J, Liu Y, et al. 2015. IL-25 elicits innate lymphoid cells and multipotent progenitor type 2 cells that reduce renal ischemic/reperfusion injury. J. Am. Soc. Nephrol. 26:2199-211
19. Cipolletta D. 2014. Adipose tissue-resident regulatory T cells: phenotypic specialization, functions and therapeutic potential. Immunology 142:517-25
20. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, et al. 2009. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15:930-39
21. Winer S, Chan Y, Paltser G, Truong D, TsuiH, et al. 2009. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 15:921-29
22. Cipolletta D, FeuererM, Li A, Kamei N, Lee J, et al. 2012. PPAR-γis amajor driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486:549-53
23. Vasanthakumar A, Moro K, Xin A, Liao Y, Gloury R, et al. 2015. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatoryTcells. Nat. Immunol. 16:276-85
24. Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, et al. 2009. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 58:2574-82
25. Carbone F, La Rocca C, Matarese G. 2012. Immunological functions of leptin and adiponectin. Biochimie 94:2082-88
26. OuchiN,Higuchi A, Ohashi K, Oshima Y,Gokce N, et al. 2010. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 329:454-57
27. McNelis JC, Olefsky JM. 2014. Macrophages, immunity, and metabolic disease. Immunity 41:36-48
28. Mathis D. 2013. Immunological goings-on in visceral adipose tissue. Cell Metab. 17:851-59
29. Kratz M, Coats BR, Hisert KB, Hagman D, Mutskov V, et al. 2014. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab. 20:614-25
30. Deng T, Lyon CJ, Minze LJ, Lin J, Zou J, et al. 2013. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab. 17:411-22
31. Biswas SK, Mantovani A. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11:889-96
32. Nishimura S,Manabe I, NagasakiM, Eto K, Yamashita H, et al. 2009. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15:914-20
33. Wensveen FM, Jelencic V, Valentic S, Sestan M, Wensveen TT, et al. 2015. NK cells link obesityinduced adipose stress to inflammation and insulin resistance. Nat. Immunol. 16:376-85
34. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 112:1821-30
35. Odegaard JI, Ricardo-Gonzalez RR, GoforthMH, Morel CR, Subramanian V, et al. 2007. Macrophagespecific PPARγcontrols alternative activation and improves insulin resistance. Nature 447:1116-20
36. ArkanMC, Hevener AL, Greten FR,Maeda S, Li ZW, et al. 2005. IKK-βlinks inflammation to obesityinduced insulin resistance. Nat. Med. 11:191-98
37. HanMS, Jung DY, MorelC, Lakhani SA, Kim JK, et al. 2013. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science 339:218-22
38. Eguchi J, Kong X, Tenta M, Wang X, Kang S, Rosen ED. 2013. Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization. Diabetes 62:3394-403
39. Bai Y, Sun Q. 2015. Macrophage recruitment in obese adipose tissue. Obes. Rev. 16:127-36
40. Hanahan D,Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144:646-74
41. Chen F, Zhuang X, Lin L, Yu P,Wang Y, et al. 2015. New horizons in tumormicroenvironment biology: challenges and opportunities. BMC Med. 13:45
42. Balkwill F, Mantovani A. 2001. Inflammation and cancer: back to Virchow? Lancet 357:539-45
43. Grivennikov SI, Greten FR, Karin M. 2010. Immunity, inflammation, and cancer. Cell 140:883-99
44. Noy R, Pollard JW. 2014. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41:49-61
45. Motz GT, Coukos G. 2011. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11:702-11
46. Dalamaga M, Diakopoulos KN, Mantzoros CS. 2012. The role of adiponectin in cancer: A review of current evidence. Endocr. Rev. 33:547-94
47. Vansaun MN. 2013. Molecular pathways: adiponectin and leptin signaling in cancer. Clin. Cancer Res. 19:1926-32
48. Gong TT, Wu QJ, Wang YL, Ma XX. 2015. Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: evidence from a meta-analysis of epidemiologic studies. Int. J. Cancer 137(8):1967-78
49. Iyengar NM, Hudis CA, Dannenberg AJ. 2015. Obesity and cancer: local and systemic mechanisms. Annu. Rev. Med. 66:297-309
50. Naugler WE, Karin M. 2008. The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14:109-19
51. Ghosh S, Ashcraft K. 2013. An IL-6 link between obesity and cancer. Front. Biosci. (Elite Ed.) 5:461-78
52. Balkwill F. 2009. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9:361-71
53. Grivennikov SI, Karin M. 2010. Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Ann. Rheum. Dis. 70(Suppl. 1):i104-8
54. Xu J, Yin Z, Cao S, Gao W, Liu L, et al. 2013. Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. PLOS ONE 8:e63654
55. Lewis AM, Varghese S, XuH, Alexander HR. 2006. Interleukin-1 and cancer progression: The emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl.Med. 4:48
56. Deng T, Cui J, Lyon CJ, Zhang N, Wang HY, et al. 2013. Inflammasomes and obesity. In Obesity, Inflammation and Cancer, ed. AJ Dannenberg, NA Berger, pp. 25-60. New York: Springer
57. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, et al. 2007. Osteopontin mediates obesityinduced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Investig. 117:2877-88
58. Rangaswami H, Bulbule A, Kundu GC. 2006. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16:79-87
59. El-Mesallamy HO, Mostafa AM, Amin AI, El Demerdash E. 2011. The interplay of YKL-40 and leptin in type 2 diabetic obese patients. Diabetes Res. Clin. Pract. 93:e113-16
60. Johansen JS. 2006. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan. Med. Bull. 53:172-209
61. Tilg H, Moschen AR. 2006. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6:772-83
62. Park J, Scherer PE. 2012. Adipocyte-derived endotrophin promotes malignant tumor progression. J. Clin. Investig. 122(11):4243-56
63. Nieman KM, Romero IL, Van Houten B, Lengyel E. 2013. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim. Biophys. Acta 1831:1533-41
64. Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, et al. 2011. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71:2455-65
65. Freese KE, Kokai L, Edwards RP, Philips BJ, Sheikh MA, Kelley J, et al. 2015. Adipose-derived stems cells and their role in human cancer development, growth, progression, and metastasis: A systematic review. Cancer Res. 75:1161-68
66. Bellows CF, Zhang Y, Simmons PJ, Khalsa AS, Kolonin MG. 2011. Influence of BMI on level of circulating progenitor cells. Obesity (Silver Spring) 19:1722-26
67. Strong AL, Burow ME, Gimble JM, Bunnell BA. 2015. Concise review: The obesity cancer paradigm: exploration of the interactions and crosstalk with adipose stem cells. Stem Cells 33:318-26
68. Moore LL, BradleeML, SingerMR,Splansky GL, ProctorMH, et al. 2004.BMIandwaist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int. J. Obes. Relat. Metab. Disord. 28:559-67
69. Huang Z,Willett WC, Colditz GA, Hunter DJ, Manson JE, et al. 1999. Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. Am. J. Epidemiol. 150:1316-24
70. Palou M, Priego T, Sanchez J, Rodriguez AM, Palou A, Pico C. 2009. Gene expression patterns in visceral and subcutaneous adipose depots in rats are linked to their morphologic features. Cell Physiol. Biochem. 24:547-56
71. Renehan AG, Frystyk J, Flyvbjerg A. 2006. Obesity and cancer risk: The role of the insulin-IGF axis. Trends Endocrinol. Metab. 17:328-36
72. Pollak M. 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8:915-28
73. Gallagher EJ, LeRoith D. 2011. Minireview: IGF, insulin, and cancer. Endocrinology 152:2546-51
74. Tsugane S, Inoue M. 2010. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 101:1073-79
75. Guilherme A, Virbasius JV, Puri V, Czech MP. 2008. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9:367-77
76. Kew MC. 2015. Obesity as a cause of hepatocellular carcinoma. Ann. Hepatol. 14:299-303
77. White DL, Kanwal F, El-Serag HB. 2012. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 10:1342-59.e2
78. Rosmorduc O, Fartoux L. 2012. HCC and NASH: How strong is the clinical demonstration? Clin. Res. Hepatol. Gastroenterol. 36:202-8
79. KitaharaCM, Berrington deGonzalez A, FreedmanND, Huxley R,Mok Y, et al. 2011. Total cholesterol and cancer risk in a large prospective study in Korea. J. Clin. Oncol. 29:1592-98
80. Rodrigues Dos Santos C, Fonseca I, Dias S, Mendes de Almeida JC. 2014. Plasma level of LDLcholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer 14:132
81. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, et al. 2012. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094-98
82. Musso G, Gambino R, CassaderM. 2013. Cholesterolmetabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid Res. 52:175-91
83. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. 2010. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140:49-61
84. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. 2005. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194-202
85. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. 2011. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364:829-41
86. Ryu TY, Park J, Scherer PE. 2014. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab. J. 38:330-36
87. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-20
88. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, et al. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-90
89. Esposito K,Nappo F, Marfella R, GiuglianoG,Giugliano F, et al. 2002. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067-72
90. Park J, Sarode VR, Euhus D, Kittler R, Scherer PE. 2012. Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer. PNAS 109:21058-63
91. Sabharwal SS, Schumacker PT. 2014. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat. Rev. Cancer 14:709-21
92. Dikalov SI, Nazarewicz RR. 2014. Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxid. Redox Signal. 19:1085-94
93. USCancer Stat. Work.Group. 2014. United States cancer statistics: 1999-2011 cancer incidence and mortality data. Rep., Dep. Health Hum. Serv., Cent. Dis. Control Prev., Natl. Cancer Inst., Atlanta. http://nccd.cdc.gov/uscs/
94. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. 2014. Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5.24 million UK adults. Lancet 384:755-65
95. Protani M, Coory M, Martin JH. 2010. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res. Treat. 123:627-35
96. Stove C, Bracke M. 2004. Roles for neuregulins in human cancer. Clin. Exp. Metastasis 21:665-84
97. Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, et al. 2013. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 5:637-45
98. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, et al. 2013. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094-98
99. Siiteri PK. 1987. Adipose tissue as a source of hormones. Am. J. Clin. Nutr. 45:277-82
100. Esfahlan RJ, Zarghami N, Esfahlan AJ, Mollazadeh M, Nejati K, Nasiri M. 2011. The possible impact of obesity on androgen, progesterone and estrogen receptors (ERαand ERβ) gene expression in breast cancer patients. Breast Cancer (Auckl.) 5:227-37
101. Newman G, Gonzalez-Perez RR. 2014. Leptin-cytokine crosstalk in breast cancer. Mol. Cell Endocrinol. 382:570-82
102. Guo S, Liu M, Wang G, Torroella-KouriM,Gonzalez-Perez RR. 2012. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim. Biophys. Acta 1825:207-22
103. Ando S, Barone I, Giordano C, Bonofiglio D, Catalano S. 2014. The multifaceted mechanism of leptin signaling within tumor microenvironment in driving breast cancer growth and progression. Front. Oncol. 4:340
104. Perrier S, Caldefie-Chezet F, Vasson MP. 2009. IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett. 583:259-65
105. Dethlefsen C, Hojfeldt G, Hojman P. 2013. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res. Treat. 138:657-64
106. Karagozian R, Derdak Z, Baffy G. 2014. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 63:607-17
107. Michelotti GA, MachadoMV, DiehlAM. 2013. NAFLD,NASHand liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10:656-65
108. Polyzos SA, Kountouras J, Mantzoros CS. 2015. Leptin in nonalcoholic fatty liver disease: A narrative review. Metabolism 64:60-78
109. Tilg H, Moschen AR. 2010. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52:1836-46
110. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. 2005. IKKβcouples hepatocyte death to cytokinedriven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121:977-90
111. Park EJ, Lee JH,YuGY,HeG, Ali SR, et al. 2010. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197-208
112. Sakurai T, Maeda S, Chang L, Karin M. 2006. Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. PNAS 103:10544-51
113. Schwabe RF, Bradham CA, Uehara T, Hatano E, Bennett BL, et al. 2003. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology 37:824-32
114. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, et al. 2010. Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17:286-97
115. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, et al. 2013. The inflammatory microenvironment in hepatocellular carcinoma: A pivotal role for tumor-associated macrophages. Biomed. Res. Int. 2013:187204
116. Fu J, Xu D, Liu Z, Shi M, Zhao P, et al. 2007. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132:2328-39
117. Wu Y, Brodt P, Sun H, Mejia W, Novosyadlyy R, et al. 2010. Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res. 70:57-67
118. Donohoe CL, O'Farrell NJ,Doyle SL, Reynolds JV. 2014. The role of obesity in gastrointestinal cancer: evidence and opinion. Ther. Adv. Gastroenterol. 7:38-50
119. Khandekar MJ, Cohen P, Spiegelman BM. 2011. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 11:886-95
120. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. 2010. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138:746-74
121. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, et al. 2008. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin. Cancer Res. 14:8221-27
122. Flossmann E, Rothwell PM. 2007. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603-13
123. Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, et al. 2015. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 313:1133-42
124. Morikawa T, Kuchiba A, Lochhead P, Nishihara R, Yamauchi M, et al. 2013. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status. Cancer Res. 73:1600-10
125. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. 2000. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of β-catenin. PNAS 97:12103-8
126. Drew JE. 2012. Molecular mechanisms linking adipokines to obesity-related colon cancer: focus on leptin. Proc. Nutr. Soc. 71:175-80
127. Hebbard L, Ranscht B. 2014. Multifaceted roles of adiponectin in cancer. Best Pract. Res. Clin. Endocrinol. Metab. 28:59-69
128. Tutino V, Notarnicola M, Guerra V, Lorusso D, Caruso MG. 2011. Increased soluble leptin receptor levels are associated with advanced tumor stage in colorectal cancer patients. Anticancer Res. 31:3381-83
129. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. 2001. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 121:79-90
130. Endo H, Hosono K, Uchiyama T, Sakai E, Sugiyama M, et al. 2011. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 60:1363-71
131. Edwards RA, Witherspoon M, Wang K, Afrasiabi K, Pham T, et al. 2009. Epigenetic repression of DNAmismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. Cancer Res. 69:6423-29
132. Moon HS, Liu X, Nagel JM, Chamberland JP, Diakopoulos KN, et al. 2013. Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut 62:561-70
133. Saxena A, Chumanevich A, Fletcher E, Larsen B, Lattwein K, et al. 2012. Adiponectin deficiency: role in chronic inflammation induced colon cancer. Biochim. Biophys. Acta 1822:527-36
134. Padidar S, Farquharson AJ, Williams LM, Kelaiditi E, Hoggard N, et al. 2011. Leptin up-regulates pro-inflammatory cytokines in discrete cells within mouse colon. J. Cell. Physiol. 226:2123-30
135. Fenton JI, Birmingham JM. 2010. Adipokine regulation of colon cancer: Adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3. Mol. Carcinog. 49:700-9
136. O'Toole A, Michielsen AJ, Nolan B, Tosetto M, Sheahan K, et al. 2014. Tumour microenvironment of both early-and late-stage colorectal cancer is equally immunosuppressive. Br. J. Cancer 111:927-32
137. Salama P, PhillipsM,Grieu F, Morris M, Zeps N, et al. 2009. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27:186-92
138. Scurr M, Ladell K, Besneux M, Christian A, Hockey T, et al. 2014. Highly prevalent colorectal cancerinfiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunol. 7:428-39
139. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. 2007. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67:10019-26
140. Yang H, Youm YH, Vandanmagsar B, Ravussin A, Gimble JM, et al. 2010. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J. Immunol. 185:1836-45
141. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. 2008. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371:569-78
142. Rosato V, Tavani A, Bosetti C, Pelucchi C, Talamini R, et al. 2011. Metabolic syndrome and pancreatic cancer risk: A case-control study in Italy and meta-analysis. Metabolism 60:1372-78
143. Grote VA, Rohrmann S, Nieters A, Dossus L, Tjonneland A, et al. 2011. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: A study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 54:3037-46
144. KangR,TangD,Lotze MT,Zeh HJ 3rd. 2012. AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy 8:989-91
145. Stolzenberg-Solomon RZ, Schairer C, Moore S,Hollenbeck A, Silverman DT. 2013. Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. Am. J. Clin. Nutr. 98:1057-65
146. Elena JW, Steplowski E, Yu K, Hartge P, Tobias GS, et al. 2013. Diabetes and risk of pancreatic cancer: A pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 24:13-25
147. Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, et al. 2013. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J. Natl. Cancer Inst. 105:95-103
148. Huang B, Cheng X, Wang D, Peng M, Xue Z, et al. 2014. Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1α signaling. Oncotarget 5:4732-45
149. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, et al. 2010. A genomewide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet. 42:224-28
150. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, et al. 2005. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294:2872-78
151. Somasundar P, Yu AK, Vona-Davis L, McFadden DW. 2003. Differential effects of leptin on cancer in vitro. J. Surg. Res. 113:50-55
152. Zyromski NJ, Mathur A, Pitt HA, Wade TE, Wang S, et al. 2009. Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery 146:258-63
153. Mendonsa AM, Chalfant MC, Gorden LD, VanSaun MN. 2015. Modulation of the leptin receptor mediates tumor growth and migration of pancreatic cancer cells. PLOS ONE 10:e0126686
154. Lesina M, Wormann SM, Neuhofer P, Song L, Algul H. 2014. Interleukin-6 in inflammatory and malignant diseases of the pancreas. Semin. Immunol. 26:80-87
155. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. 2004. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101:2727-36
156. Angst E, Reber HA, Hines OJ, Eibl G. 2008. Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery 144:57-65
157. Muerkoster S, Wegehenkel K, Arlt A, Witt M, Sipos B, et al. 2004. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1β. Cancer Res. 64:1331-37
158. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, et al. 2012. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399-405
159. Pylayeva-Gupta Y, Lee KE,Hajdu CH,MillerG, Bar-SagiD. 2012. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21:836-47
160. Khasawneh J, Schulz MD, Walch A, Rozman J, Hrabe de Angelis M, et al. 2009. Inflammation and mitochondrial fatty acid β-oxidation link obesity to early tumor promotion. PNAS 106:3354-59
161. Ben-Neriah Y, Karin M. 2011. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 12:715-23
162. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. 2007. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67:9518-27
163. Mace TA, Ameen Z, Collins A,Wojcik S, Mair M, et al. 2013. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 73:3007-18
164. Bayne LJ, Beatty GL, Jhala N, ClarkCE, Rhim AD, et al. 2012. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21:822-35
165. Yokota T, Oritani K, Takahashi I, Ishikawa J,Matsuyama A, et al. 2000. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723-32
166. Clement K, ViguerieN, PoitouC, Carette C, Pelloux V, et al. 2004. Weight loss regulates inflammationrelated genes in white adipose tissue of obese subjects. FASEB. J. 18:1657-69
167. Nicklas BJ, Ambrosius W, Messier SP, Miller GD, Penninx BW, et al. 2004. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: A randomized controlled clinical trial. Am. J. Clin. Nutr. 79:544-51
168. Lakhdar N, Denguezli M, Zaouali M, Zbidi A, Tabka Z, Bouassida A. 2013. Diet and diet combined with chronic aerobic exercise decreases body fat mass and alters plasma and adipose tissue inflammatory markers in obese women. Inflammation 36:1239-47
169. Kong LC, Wuillemin PH, Bastard JP, Sokolovska N, Gougis S, et al. 2013. Insulin resistance and inflammation predict kinetic body weight changes in response to dietary weight loss and maintenance in overweight and obese subjects by using a Bayesian network approach. Am. J. Clin. Nutr. 98:1385-94
170. Pendyala S, Neff LM, Suarez-Farinas M, Holt PR. 2011. Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am. J. Clin. Nutr. 93:234-42
171. Raju J, Bird RP. 2003. Energy restriction reduces the number of advanced aberrant crypt foci and attenuates the expression of colonic transforming growth factorβand cyclooxygenase isoforms in Zucker obese (fa/fa) rats. Cancer Res. 63:6595-601
172. Fabian CJ, Kimler BF, Donnelly JE, Sullivan DK, Klemp JR, et al. 2013. Favorablemodulation of benign breast tissue and serum risk biomarkers is associated with >10% weight loss in postmenopausal women. Breast Cancer Res. Treat. 142:119-32
173. Rapp K, Klenk J, Ulmer H, Concin H, Diem G, et al. 2008. Weight change and cancer risk in a cohort of more than 65,000 adults in Austria. Ann. Oncol. 19:641-48
174. Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS. 2005. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: A time course study. Obes. Surg. 15:474-81
175. Schauer PR, Ikramuddin S, GourashW, Ramanathan R, Luketich J. 2000. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann. Surg. 232:515-29
176. Arterburn DE, Courcoulas AP. 2014. Bariatric surgery for obesity and metabolic conditions in adults. BMJ 349:g3961
177. Maestro A, Rigla M, Caixas A. 2015. Does bariatric surgery reduce cancer risk? A review of the literature. Endocrinol. Nutr. 62:138-43
178. Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, et al. 2009. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): A prospective, controlled intervention trial. Lancet Oncol. 10:653-62
179. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, et al. 2009. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 17:796-802
180. Upala S, Anawin S. 2015. Bariatric surgery and risk of postoperative endometrial cancer: A systematic review and meta-analysis. Surg. Obes. Relat. Dis. 11(4):949-55
181. Afshar S, Kelly SB, Seymour K, Lara J, Woodcock S, Mathers JC. 2014. The effects of bariatric surgery on colorectal cancer risk: systematic review and meta-analysis. Obes. Surg. 24:1793-99
182. Derogar M, Hull MA, Kant P, Ostlund M, Lu Y, Lagergren J. 2013. Increased risk of colorectal cancer after obesity surgery. Ann. Surg. 258:983-88
183. Yang L, Colditz GA. 2015. Prevalence of overweight and obesity in theUnited States, 2007-2012. JAMA Intern. Med. 175(8):1412-13
184. Bowers LW, Maximo IX, Brenner AJ, Beeram M, Hursting SD, et al. 2014. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions. Cancer Res. 74:4446-57
185. Cui Y, Deming-Halverson SL, ShrubsoleMJ, Beeghly-Fadiel A, Cai H, et al. 2014. Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Res. Treat. 146:439-46
186. Shebl FM, Hsing AW, Park Y, Hollenbeck AR, Chu LW, et al. 2014. Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study. PLOS ONE 9:e114633